• 공지사항
  • Journal of Gynecologic Oncology March 2021, Volume 32 Issue 2

    조회수 : 457 게시일 : 2021-03-31
    Table of Contents
    Volume 32(2); March 2021
    Editorials
      jgo.2021.32.e35
    Increased risk of herpes zoster in gynecological cancer patients receiving radiotherapy combined with chemotherapy: a need for paying attention to vaccines

    Shin DH, Song KH.
      jgo.2021.32.e36
    How to start niraparib in real-world Asian ovarian cancer patients?

    Hong SH.
      jgo.2021.32.e34
    Current status and future directions of ovarian cancer prognostic models

    Kobayashi Y, Banno K, Aoki D.
      jgo.2021.32.e33
    Comments on: Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer

    Kwon JS.
      jgo.2021.32.e39
    Evaluating robotic surgical courses: structured training matters

    Falconer H.
      jgo.2021.32.e47
    Post-LACC era: critical assessment not “all-or-none” is needed

    Leitao MM, Kim SI, Kim JW.
      jgo.2021.32.e38
    Lumping and splitting: The need for precision medicine and “personomics” in endometrial cancer

    Reyes-Baez FE, Garzon S, Mariani A.
      jgo.2021.32.e50
    Comments on: Safety and efficacy of 3D-printed templates assisted CT-guided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy

    Shin HS.
    Practice Guideline
      jgo.2021.32.e49
    The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer

    Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, Satoh T, Hirashima Y, Matsumura N, Yokoyama Y, Kawana K, Kyo S, Aoki D, Katabuchi H.
    Original Articles
    Cervix
      jgo.2021.32.e15
    Safety and efficacy of 3D-printed templates assisted CT-guided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy

    Liu Y, Jiang P, Zhang H, Wang J.
      jgo.2021.32.e17
    Comparison between laparoscopic and abdominal radical hysterectomy for stage IB1 and tumor size <2 cm cervical cancer with visible or invisible tumors: a multicentre retrospective study

    Li P, Chen L, Ni Y, Liu J, Li D, Guo J, Liu Z, Jin S, Xu Y, Li Z, Wang L, Bin X, Lang J, Liu P, Chen C.
    Uterine Corpus
      jgo.2021.32.e11
    Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer

    Tortorella L, Restaino S, Zannoni GF, Vizzielli G, Chiantera V, Cappuccio S, Gioè A, La Fera E, Dinoi G, Angelico G, Scambia G, Fanfani F.
      jgo.2021.32.e22
    Recurrence risk factors in stage IA grade 1 endometrial cancer

    Nwachukwu C, Baskovic M, Von Eyben R, Fujimoto D, Giaretta S, English D, Kidd E.
    Ovary
      jgo.2021.32.e16
    Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer

    Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T.
      jgo.2021.32.e18
    Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients

    Lu HY, Tai YJ, Chen YL, Chiang YC, Hsu HC, Cheng WF.
      jgo.2021.32.e21
    Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer

    Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N.
      jgo.2021.32.e23
    Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer

    Jung Y, Hur S, Liu J, Lee S, Kang BS, Kim M, Choi YJ.
      jgo.2021.32.e27
    Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore

    Tan DS, Chan JJ, Hettle R, Ghosh W, Viswambaram A, Yu CC.
    Education
      jgo.2021.32.e26
    Implementation and evaluation of a novel subspecialty society fellows robotic surgical course: the SGO minimally invasive academy surgical curriculum

    Boitano TK, Smith HJ, Cohen JG, Rossi EC, Kim KH.
    Supportive Care
      jgo.2021.32.e13
    Radiotherapy combined with chemotherapy increases the risk of herpes zoster in patients with gynecological cancers: a nationwide cohort study

    Lee PY, Lai JN, Chen SW, Lin YC, Chiu LT, Wei YT.
    Clinical Trial Protocol
      jgo.2021.32.e31
    A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)

    Lee YJ, Lim MC, Kim BG, Ngoi NY, Choi CH, Park SY, Tan DS, Go Y, Lee JY.
    Review Article
      jgo.2021.32.e25
    Lymphadenectomy issues in endometrial cancer

    Konno Y, Asano H, Shikama A, Aoki D, Tanikawa M, Oki A, Horie K, Mitsuhashi A, Kikuchi A, Tokunaga H, Terao Y, Satoh T, Ushijima K, Ishikawa M, Yaegashi N, Watari H.
    Correspondence
      jgo.2021.32.e24
    Hospital volume-outcome relationship in vulvar cancer treatment: a Japanese Gynecologic Oncology Group study

    Matsuo K, Nishio S, Matsuzaki S, Machida H, Mikami M.
    Society News
      jgo.2021.32.e41
    Reviewer recognition in 2020

    Journal of Gynecologic Oncology (JGO) Editorial Office.